Perfil del autor: Cruz Merino, Luis de la
Datos institucionales
| Nombre | Cruz Merino, Luis de la |
| Departamento | Medicina |
| Área de conocimiento | Medicina |
| Categoría profesional | Profesor Titular de Universidad (Pza. V) |
| Correo electrónico | Solicitar |
 |
|
Estadísticas
-
Nº publicaciones
73
-
Nº visitas
3901
-
Nº descargas
2856
| Publicaciones |
|---|
Artículo
 Dendritic cells: the yin and yang in disease progression
(Frontiers Media, 2024)
Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive immunity. DCs have been historically ... |
Artículo
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
(BMC, 2024)
Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival ... |
Artículo
Cancer nano-immunotherapy: the novel and promising weapon to fight cancer
(Mdpi Ag, 2024)
Cancer is a complex disease that, despite advances in treatment and the greater understanding of the tumor biology until ... |
Artículo
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
(Oxford University Press, 2024)
Background: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator’s ... |
Artículo
Prognostic implications of the residual tumor microenvironment after neoadjuvant chemotherapy in triple-negative breast cancer patients without pathological complete response
(MDPI, 2023)
With a high risk of relapse and death, and a poor or absent response to therapeutics, the triple-negative breast cancer ... |
Artículo
Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report
(Frontiers Media S.A., 2023)
Nowadays, immune checkpoint inhibitors (ICI) have become the cornerstone of treatment for many tumors, either as monotherapy ... |
Artículo
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
(BMC, 2023)
Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and ... |
Artículo
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
(American Association Cancer Research, 2023)
lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in ... |
Artículo
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
(Sage Journals, 2023)
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression free survival (PFS) compared ... |
Artículo
A genetic profling guideline to support diagnosis and clinical management of lymphomas
(Springer Nature, 2023)
The new lymphoma classifcations (International Consensus Classifcation of Mature Lymphoid Neoplasms, and 5th World Health ... |
Artículo
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
(American Society of Clinical Oncology, 2023)
PURPOSE Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate ... |
Artículo
Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells
(Mdpi Ag, 2023)
Breast cancer (BC) continues to be the most diagnosed tumor in women and a very heterogeneous disease both inter- and ... |
Artículo
Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
(Mdpi Ag, 2023)
Triple-negative breast cancer (TNBC) is particularly challenging due to the weak or absent response to therapeutics and ... |
Artículo
Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
(Frontiers Media S.A., 2023)
The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in ... |
Artículo
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving frst-line ribociclib plus fulvestrant
(Biomed Central LTD, 2023)
Background The phase III MONALEESA-3 trial included frst- (1L) and second-line (2L) patients and demonstrated a signifcant ... |
Artículo
 Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization
(Frontiers Media S.A., 2023)
SARS-CoV-2 infection is the cause of the disease named COVID-19, a major public health challenge worldwide. Differences ... |
Artículo
Obesity and Risk for Lymphoma: Possible Role of Leptin
(MDPI, 2022)
Obesity, which is considered a pandemic due to its high prevalence, is a risk factor for many types of cancers, including ... |
Artículo
The effects of dendritic cell-based vaccines in the tumor microenvironment Impact on myeloid-derived suppressor cells
(Frontiers Media, 2022)
Dendritic cells (DCs) are a heterogenous population of professional antigen presenting cells whose main role is diminished ... |
Artículo
Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies
(MDPI, 2022)
Ewing Sarcoma (EWS) is an aggressive bone and soft tissue tumor that mainly affects children, adolescents, and young adults. ... |
Tesis Doctoral
Immune Biomarkers In Peripheral Blood In Patients With HER2 Negative Advanced Breast Cancer Treated With A Chemoimmunotherapy Schedule Based On Pembrolizumab And Gemcitabine. – Translational Substudy Of The PANGEA- Breast Cancer Trial (GEICAM/2015-04)
(2022)
Within the last years, immune checkpoint inhibitors (ICI) have constituted a major breakthrough in cancer research. These ... |
Artículo
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
(Elsevier Science Ltd, 2022)
Abstract Purpose: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled ... |
Artículo
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
(MDPI, 2022)
BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant–adjuvant pertuzumab–trastuzumab-based therapy for ... |
Artículo
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
(Elsevier, 2022)
Background: Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish ... |
Artículo
Low levels of granulocytic myeloid-derived suppressor cells may be a good marker of survival in the follow-up of patients with severe COVID-19
(Frontiers Media S.A., 2022)
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, ... |
Artículo
Genes involved in immune reinduction may constitute biomarkers of response for metastatic melanoma patients treated with targeted therapy
(MDPI, 2022)
Targeted therapy in metastatic melanoma often achieves a major tumour regression response and significant long-term survival ... |
Artículo
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
(ELSEVIER SCI LTD, 2022)
Background The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor ... |
Artículo
Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
(Elsevier Science Ltd, 2022)
Abstract Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected ... |
Artículo
Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases
(Frontiers Media S.A., 2022)
Immunosuppressant conditions such as hematological malignancies increase the risk of severe acute respiratory syndrome ... |
Artículo
The complexity of cancer immunotherapy illustrated through skin tumors
(Wichtig Editore, 2022)
Skin tumours are among the cancer types most sensitive to immunotherapy, due to their unique immunogenic features including ... |
Artículo
Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
(MDPI, 2022)
Lymphoma is a neoplasm arising from B or T lymphocytes or natural killer cells characterized by clonal lymphoproliferation. ... |
Artículo
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
(AMER ASSOC CANCER RESEARCH, 2022)
Purpose: New therapeutic options are needed in relapsed/refrac tory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide ... |
Artículo
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
(Nature Research, 2021)
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with ... |
Artículo
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
(MDPI, 2021)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term ... |
Artículo
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial
(MDPI, 2021)
The search of prognostic factors is a priority in diffuse large B-cell lymphoma (DLBCL) due to its aggressiveness. We have ... |
Artículo
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
(BMJ Publishing Group, 2021)
Background Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding ... |
Artículo
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
(Nature Publishing Group, 2021)
Identification of the different elements intervening at the tumor microenvironment seems key to explain clinical evolution ... |
Artículo
Immunometabolism modulation in therapy
(MDPI, 2021)
The study of cancer biology should be based around a comprehensive vision of the entire tumor ecosystem, considering the ... |
Tesis Doctoral
Análisis del perfil de respuesta inmune en sangre periférica inducido por tratamiento sistémico en el carcinoma de mama avanzado
(2021)
La identificación de los diferentes elementos que intervienen en el proceso de inmunoedición, parece clave para explicar ... |
Artículo
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
(Elsevier, 2021)
Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) ... |
Artículo
Leptin, both bad and good actor in cancer
(MDPI, 2021)
Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many ... |
Artículo
Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature
(MDPI, 2021)
Background. Isolated limb perfusion (ILP) is a locoregional procedure indicated by the unresectable melanoma of the limbs. ... |
Artículo
Metabolic classification and intervention opportunities for tumor energy dysfunction
(MDPI, 2021)
A comprehensive view of cell metabolism provides a new vision of cancer, conceptualized as tissue with cellular-altered ... |
Artículo
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
(BMJ, 2021)
Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, ... |
Artículo
SEOM clinical guideline for the management of cutaneous melanoma (2020)
(Springer Nature, 2021)
Melanoma afects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology ... |
Artículo
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study
(American Association for Cancer Research, 2021)
Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and ... |
Artículo
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
(Nature publishing group, 2021)
Identifcation of the diferent elements intervening at the tumor microenvironment seems key to explain clinical evolution ... |
Tesis Doctoral
Estudio poblaciones celulares en pacientes con linfoma difuso de células B grandes refractarios o en recaída: papel de las células supresoras de origen mieloide en respuesta al tratamiento R2-GDP
(2020)
La inmunoedición, que se caracteriza por el escape que realizan las células malignas de la inmunovigilancia antitumoral, ... |
Tesis Doctoral
Caracterización del perfil inmunitario en sangre periférica y en tejido de carcinoma de mama con tratamiento neoadyuvante. Estudio de su potencial papel pronóstico y predictivo de respuesta
(2020)
Introducción: Los estudios traslacionales permiten una correcta interrelación entre la investigación básica y la clínica. ... |
Artículo
Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
(Lippincott Williams & Wilkins, 2020)
Introduction: Leptomeningeal dissemination due to HER2-overexpressing breast cancer is a rare and hard to treat complication ... |
Artículo
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
(Springer, 2020)
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. ... |
Artículo
GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain
(2020)
Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARS-CoV-2 ... |
Artículo
Integrating the tumor microenvironment into cancer therapy
(MDPI, 2020)
Tumor progression is mediated by reciprocal interaction between tumor cells and their surrounding tumor microenvironment ... |
Artículo
Obesity and Breast Cancer: Role of Leptin
(2019)
Obesity-related breast cancer is an important threat that affects especially post-menopausal women. The link between obesity ... |
Artículo
Development and validation of a sexual relations satisfaction scale in patients with breast cancer — “SEXSAT-Q”
(Biomed Central LTD, 2019)
Purpose: Because the currently available questionnaires to evaluate sexual changes on breast cancer women only address the ... |
Artículo
Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy
(Amer Publ Co, 2019)
Background: Immune escape of tumor cells is a new hallmark of cancer in general, and breast cancer, in particular. Previous ... |
Artículo
The tumour microenvironment as an integrated framework to understand cancer biology
(Elsevier Ireland Ltd, 2019)
Cancer cells all share the feature of being immersed in a complex environment with altered cell-cell/cell-ex tracellular ... |
Artículo
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
(Springer, 2019)
Although the metastasic breast cancer is still an incurable disease, recent advances have increased signifcantly the time ... |
Artículo
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
(BMC, 2019)
Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune ... |
Artículo
New horizons in breast cancer: the promise of immunotherapy
(Springer, 2019)
Immunology and immunotherapy of cancer is an expanding feld in oncology, with recent great achievements obtained through ... |
Artículo
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
(Public Library Science, 2019)
Follicular lymphoma (FL) is an indolent but largely incurable disease. Some patients suffer histological transformation ... |
Artículo
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
(BMC, 2018)
Background: Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients ... |
Artículo
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
(Nature publishing group, 2018)
Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo ... |
Artículo
2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary
(Springer, 2018)
Cancer of unknown primary (CUP) is defned as a heterogeneous group of tumours that present with metastasis, and in which ... |
Artículo
SEOM clinical guideline for the management of malignant melanoma (2017)
(Springer Int Publ Ag, 2018)
All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when ... |
Artículo
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
(Oxford University Press, 2018)
Background: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity ... |
Artículo
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF‑mutated melanoma treated in the randomized coBRIM study
(Biomed Central LTD, 2017)
Background: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the ... |
Artículo
Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells
(Public Library Science, 2016)
Obesity is a well-known risk factor for breast cancer development in postmenopausal women. High insulin and leptin levels ... |
Artículo
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
(Springer, 2015)
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL ... |
Artículo
SEOM clinical guidelines in metastatic breast cancer 2015
(Springer, 2015)
Metastatic breast cancer is essentially an incurable disease. However, recent advances have resulted in a significant ... |
Artículo
SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma
(Springer, 2015)
Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph ... |
Artículo
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor-positive, HER2-negative, node-negative early-stage breast cancer
(Taylor and Francis Group, 2015)
Purpose: Improved understanding of risk of recurrence (ROR) is needed to reduce cases of recurrence and more effectively ... |
Artículo
New insights into the role of the immune microenvironment in breast carcinoma
(2013)
Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clinical trials in breast ... |
Artículo
Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety
(Oxford Academic, 2010)
Background. Isolated limb perfusion (ILP) involves the administration of chemotherapy drugs directly into a limb involved ... |